NOVN/ROG/IONS/CALTX/AZN: Factor B lacking the X Factor in IgAN

Following the success of Novartis’ Factor B complement inhibitor Fabhalta, Roche has partnered with IONIS to exploit Factor B inhibition through a form of gene therapy known as antisense oligonucleotide (ASO). However...